National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Upadacitinib (Rinvoq®) for atopic dermatitis. HTA ID: 21029

Upadacitinib (Rinvoq®) for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older, who are candidates for systemic therapy.


NCPE Assessment Process Complete
Rapid review commissioned 05/07/2021
Rapid review completed 29/07/2021
Rapid Review outcome A full HTA is not recommended. The NCPE recommends that upadacitinib should not be considered for reimbursement at the submitted price.*


*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.